Eli Lilly (LLY) Reports $12.9 Billion in GLP-1 Drug Sales
Published on · Source: marketwatch.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) reported sales of $12.9 billion from its GLP-1 drugs every three months. The company stated that the tirzepatide franchise had a strong quarter, indicating significant market demand. This growth reflects the increasing adoption of these drugs as part of diabetes treatment. The positive sales performance could impact investor sentiment and market positioning for LLY as it continues to expand in the pharmaceutical sector.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Novartis (NVS) drug trials target Lp(a) for heart disease prevention
- Eli Lilly (LLY) Plans $7B Acquisition, P/E at 40 Amid Growth
- Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
- Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
- Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
